A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C

• ClinicalTrials.gov Identifier: NCT02435030
• Recruitment Status: Completed
• First Posted: May 6, 2015
• Last Update Posted: May 18, 2017
• Sponsor: Orphazyme
• Information provided by (Responsible Party): Orphazyme

Tracking Information

• First Submitted Date: April 22, 2015
• First Posted Date: May 6, 2015
• Last Update Posted Date: May 18, 2017
• Study Start Date: September 2015
• Actual Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 3, 2015)

• NP-C clinical disease severity [ Time Frame: at week 0 and week 24-28 ]
  Change in NP-C Clinical Severity scale
• Quality of life questionnaire (EQ-5D-Y) [ Time Frame: at week 0 and week 24-28 ]
  Change in the Quality of life
• Ultrasonographic evaluation of liver and spleen [ Time Frame: at week 0 and week 24-28 ]
  Changes in the size and/or characteristics of the liver and spleen (assessed by ultrasound).
• Oxysterol [ Time Frame: at week 0 and week 24-28 ]
  Change in Oxysterol concentrations
• NPC clinical symptoms [ Time Frame: at week 0 and week 24-28 ]
  Change in NPC clinical symptoms
• NPC protein [ Time Frame: at week 0 and week 24-28 ]
  Change in NPC protein concentrations

Original Primary Outcome Measures (submitted: April 30, 2015)

• NP-C clinical disease severity [ Time Frame: at week 0 and week 24-28 ]
  Change in NP-C Clinical Severity scale
• Quality of life questionnaire (EQ-5D-Y) [ Time Frame: at week 0 and week 24-28 ]
  Change in the Quality of life
• CNS changes (MRI and MRS) [ Time Frame: at week 0 and week 24-28 ]
  Changes in the central nervous system (CNS) structure and function (assessed by magnetic resonance imaging [MRI] and magnetic resonance spectroscopy [MRS]);
• Ultrasonographic evaluation of liver and spleen [ Time Frame: at week 0 and week 24-28 ]
  Changes in the size and/or characteristics of the liver and spleen (assessed by ultrasound).
• Oxysterol [ Time Frame: at week 0 and week 24-28 ]
  Change in Oxysterol concentrations
• NPC clinical symptoms [ Time Frame: at week 0 and week 24-28 ]
  Change in NPC clinical symptoms
• NPC protein [ Time Frame: at week 0 and week 24-28 ]
  Change in NPC protein concentrations

Current Secondary Outcome Measures (submitted: April 30, 2015)

Safety Parameters [ Time Frame: at week 0 and week 24-28 ]

Adverse events (AEs) (disease related and treatment related), haematology, clinical chemistry, physical examination, vital signs and electrocardiogram (ECG).

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C
• Official Title: A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern

Brief Summary

This is a prospective non-therapeutic observational study in NP-C patients. The aim is to characterize the individual patient disease progression profile through the historical and 6 months prospective evaluation of clinical, imaging, biological(biomarkers) and quality of life data.

Patients will be offered enrollment into a Phase II/III study on arimoclomol at the end of the study.

• Detailed Description: Not Provided
• Study Type: Observational
• Study Design: Observational Model: Case-Only; Time Perspective: Prospective
• Target Follow-Up Duration: Not Provided

Biospecimen

Retention:   Samples Without DNA

Description:

Plasma

• Sampling Method: Probability Sample
• Study Population: NPC1 and NPC2 patients aged 2-18 years
• Condition: Niemann-Pick Disease, Type C
• Intervention: Not Provided

Study Groups/Cohorts

NP-C Patients

NPC type 1 or 2 patients aged 2-18 years

• Publications *: Mengel E, Bembi B, Del Toro M, Deodato F, Gautschi M, Grunewald S, Grønborg S, Héron B, Maier EM, Roubertie A, Santra S, Tylki-Szymanska A, Day S, Symonds T, Hudgens S, Patterson MC, Guldberg C, Ingemann L, Petersen NHT, Kirkegaard T, Í Dali C. Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study. Orphanet J Rare Dis. 2020 Nov 23;15(1):328. doi: 10.1186/s13023-020-01616-0.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: April 3, 2017): 35
• Original Estimated Enrollment (submitted: April 30, 2015): 46
• Actual Study Completion Date: May 2017
• Actual Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Written informed consent (and assent if appropriate to local laws and regulations) prior to any study-related procedures;
• Males and females aged from 2 years to 18 years and 11 months;
• Patients of any ethnic background will be eligible for this study;
• Patient weight ≥15th percentile of body mass index (BMI) for age according to the World Health Organisation (WHO) standards;
• Diagnosis of Niemann Pick disease Type C (NP-C), either NPC1 or NPC2;
• NP-C diagnosis genetically confirmed (deoxyribonucleic acid [DNA] sequence analysis);
• Both NPC1 and NPC2 patients are eligible;
• Presenting at least one neurological symptom of the disease (for example, but not limited to, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, or dysphagia);
• Ability to walk either independently or with assistance;
• Ability to travel to the corresponding clinical trial site repeatedly (every 6 months) for evaluation and follow-up;
• Treated or non-treated with miglustat;
• If a patient is under prescribed treatment with miglustat, it has to be under stable dose of the medication for ≥ 3 continuous months prior to inclusion in the study;
• Sexually active patients must be willing and able to use an adequate method of contraception throughout the study, for example: diaphragm + spermicide; intrauterine contraceptive device; oral contraceptives; implant; injection of a progestogen medication;
• Ability to comply with the protocol-specified procedures/evaluations and scheduled visits;
• Willing to participate in all aspects of trial design including serial blood sampling, skin biopsies and imaging (ultrasonography) collections.

Exclusion Criteria:

• No written informed consent obtained from the patient or their parent(s)/legal guardian(s) (and assent if appropriate to local laws and regulation) before any study related procedures;
• Recipient of a liver transplant or planned liver transplantation;
• Patients with uncontrolled severe epileptic seizures period (at least 3 consecutive severe epileptic seizures that required medication) within 2 months prior to the written consent. This includes patients with ongoing seizures that are not stable in frequency or type or duration over a 2 month period prior to enrollment, requiring change in dose of antiepileptic medication (other than adjustment for weight) over a 2 month period prior to enrollment, or requiring 3 or more antiepileptic medications to control seizures;
• Neurologically asymptomatic patients;
• Severe liver insufficiency (defined as hepatic laboratory parameters, aspartate transaminase [AST] and alanine transaminase [ALT] greater than three-times the upper limit of normal for age and gender;
• Severe renal insufficiency, with serum creatinine level greater than 1.5 times the upper limit of normal ;
• Severe manifestations of NP-C disease that would interfere with the patient's ability to comply with the requirements of this protocol;
• In the opinion of the Investigator, the patient's clinical condition does not allow for the required blood collection and/or skin biopsies as per the protocol-specified procedures;
• Treatment with any IMP within 4 weeks prior to the study enrollment;
• Treatment with any IMP during the study in an attempt to treat NP-C;
• Current participation in another trial is not permitted unless it is a non-interventional study and the sole purpose of the trial is for long-term follow up/survival data (registry);
• Patients will be excluded if there is a confirmed risk linked to the MRI procedure to be performed in the subsequent therapeutic interventional study [i.e.: implanted cardiac pacemaker or implantable cardioverter defibrillator, implanted neural pacemakers, cochlear implants, implanted metallic foreign bodies in the eye or CNS (such as a CNS aneurysmal clip), any form of implanted wire or metal device that may concentrate radio frequency fields and/or confirmed history of unexpected serious adverse reaction to sedation or anesthesia (if sedation is necessary)];
• Patients will be excluded if there is a confirmed risk linked to the skin punch biopsy procedure like severe thrombocytopaenia, at investigator's discretion.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 2 Years to 18 Years (Child, Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Denmark, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom

Administrative Information

• NCT Number: NCT02435030
• Other Study ID Numbers: CT-ORZY-NPC-001; 2014-005194-37 ( EudraCT Number )
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: Orphazyme
• Study Sponsor: Orphazyme
• Collaborators: Not Provided

Investigators

• Principal Investigator: Karl-Eugen Mengel; Villa Metabolica, Mainz, Germany

• PRS Account: Orphazyme
• Verification Date: May 2017